2 assets in Neuroendocrine Tumor Of The Anal Canal

Therapeutic assets addressing Neuroendocrine Tumor Of The Anal Canal, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Neuroendocrine Tumor Of The Anal Canal	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Neuroendocrine Tumor Of The Anal Canal	National Cancer Institute (NCI)	P2	CCC (53)